Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4767-4777

  Montanaro, Lorenzo ^a   Calienni, Maria ^a   Bertoni, Sara ^a   Rocchi, Laura ^a   Sansone, Pasquale ^a,b   Storci, Gianluca ^a,b   Santini, Donatella ^b   Ceccarelli, Claudio ^a,b   Taffurelli, Mario ^a   Carnicelli, Domenica ^a   Brigotti, Maurizio ^a   Bonafè, Massimiliano ^a,b   Treré, Davide ^a   Derenzini, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; MESSENGER RNA; PROTEIN P53; SMALL INTERFERING RNA; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL RIBOSOME ENTRY SITE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; STEM CELL; TRANSLATION INITIATION; WILD TYPE;

EID: 77953143023     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4024     Document Type: Article

References (50)

1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-283
2. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299
3. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
4. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
6. Linares LK, Hengstermann A, Ciechanover A, Müller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 2003;100:12009-12014
7. Danovi D, Meulmeester E, Pasini D, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004;24:5835-5843
8. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-2991
9. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature 2008;451:76-80.
10. Hollstein M, Hainaut P. Massively regulated genes: the example of TP53. J Pathol 2010;220:164-173
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311
12. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 1995;14:4442-4449
13. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005;123:49-63.
14. Grover R, Raym PS, Das S. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 2008;7:2189-2198
15. Yang DQ, Halaby MJ, Zhan Y. The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006;25:4613-4619
16. Schneider RJ, Sonenberg N. Translational control in cancer development and progression. In: Translational control in biology and medicine. In: Mathews MB, Sonenberg N, Hershey JWB, editors. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2007.
17. Meier UT. The many facets of H/ACA ribonucleoproteins. Chromosoma 2005;114:1-14.
18. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006;312:902-906
19. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998;19:32-38
20. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000;110:768-779
21. Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003;299:259-262
22. Montanaro L, Brigotti M, Clohessy J, et al. Dyskerin expression influences the level ofribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol 2006;210:10-18
23. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-1270
24. Petronini PG, Tramacere M, Mazzini A, Piedimonte G, Silvotti L, Borghetti AF. Hyperosmolarity-induced stress proteins in chick embryo fibroblasts. Exp Cell Res 1987;172:450-462
25. Chaudhuri S, Vyas K, Kapasi P, et al. Human ribosomal protein L13a is dispensable for canonical ribosome function but indispensable for efficient rRNA methylation. RNA 2007;13:2224-2237
26. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-259
27. Holcik M. Translational upregulation of the X-linked inhibitor of apoptosis. Ann N Y Acad Sci 2003;1010:249-258
28. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174
29. Kaluzová M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004;24:5757-5766
30. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 2005;331:718-725
31. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002.
32. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 2006;99:97-101.
33. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715
34. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003;100:1931-1936
35. Yan J, Yun H, Yang Y, Jing B, Feng C, Song-bin F. Upregulation of BNIP3 promotes apoptosis of lung cancer cells that were induced by p53. Biochem Biophys Res Commun 2006;346:501-507
36. Storci G, Sansone P, Trere D, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008;214:25-38.
37. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005;7:86-95.
38. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. Bio Drugs 2007;21:299-310.
39. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555
40. Wong JM, Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 2006;20:2848-2858
41. Montanaro L, Calienni M, Ceccarelli C, et al. Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell Oncol 2008;30:483-490
42. Braunstein S, Karpisheva K, Pola C, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007;28:501-512
43. Gu BW, Bessler M, Mason PJ. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci U S A 2008;105:10173-10178
44. Wang C, Query CC, Meyer UT. Immunopurified small nucleolar ribonucleoprotein particles pseudouridylate rRNA independently of their association with phosphorylated Nopp140. Mol Cell Biol 2002;22:8457-8466
45. Montanaro L, Trere D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol 2008;173:301-310
46. Kullmann M, Göpfert U, Siewe B, Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes Dev 2002;16:3087-3099
47. Wilker EW, van Vugt MA, Artim SA, et al. 14-3-3σ controls mitotic translation to facilitate cytokinesis. Nature 2007;446:329-332
48. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008;456:971-975
49. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-76
50. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-325.